Resources & News

In rare diseases, true patient engagement is critical to every step of a drug's development, from clinical trials and regulatory approval, to patient diagnosis and adherence. Why is that? Because patients with rare diseases (and their families) are essentially the...

The healthcare environment has changed almost beyond recognition in the past decade and this has been well documented. One of the key upshots of the turbulence caused by healthcare reforms, patent cliffs, drying product pipelines, fiscal restraint and a host of other...

With increasing pressures on healthcare systems, the rise in power of different stakeholders such as payers, patients and policy makers, and the launch of highly specialised/rare treatments, such as personalised medicines, the traditional go-to-market models for...

Historically, the pharma sector was able to focus oon demand generation after obtaining marketing authorisations for its drugs. But today, it is difficult to find the individual decision-maker who can make an autonomous decision given the widespread influence of...

There was a time where regulatory process, promotional regulations and therapeutic guidelines were organized on a national basis. During the last 20 years, the EU has increasingly centralized and harmonized regulatory procedures and promotional practices; even access...

Therapeutic area leadership was once defined simply by who had the biggest and best drug for that condition; the level of leadership could usually be measured by sales figures, but times have changed. Individual products are still undoubtedly the most important...

Outcommes data are the holy grail of drug development and market access. Everyone involved in healthcare – physicians, patients, governments and in particular payers – wants to see incontestable proof that the introduction of a new drug will result in meaningful and...